NASDAQ:IMMP Prima BioMed H2 2026 Earnings Report $0.37 +0.01 (+1.42%) Closing price 09/1/2026 04:00 PM EasternExtended Trading$0.38 +0.00 (+1.02%) As of 07:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Prima BioMed EPS ResultsActual EPSN/AConsensus EPS -$0.03Beat/MissN/AOne Year Ago EPSN/APrima BioMed Revenue ResultsActual RevenueN/AExpected Revenue$11.73 millionBeat/MissN/AYoY Revenue GrowthN/APrima BioMed Announcement DetailsQuarterH2 2026Date8/30/2026TimeBefore Market OpensConference Call DateSunday, August 30, 2026Conference Call Time6:00PM ETConference Call ResourcesAnnual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report Prima BioMed Earnings HeadlinesShort Interest in Prima BioMed Ltd (NASDAQ:IMMP) Decreases By 36.4%August 31 at 2:20 AM | americanbankingnews.comPrima BioMed (NASDAQ:IMMP) Stock Price Crosses Below 50-Day Moving Average - Time to Sell?August 26, 2026 | americanbankingnews.comGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold. One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project.September 2 at 1:00 AM | Wall Street Logic (Ad)Prima BioMed (IMMP) Expected to Release Earnings on WednesdayAugust 26, 2026 | americanbankingnews.comImmutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004July 13, 2026 | globenewswire.comImmutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMPJuly 6, 2026 | prnewswire.comSee More Prima BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prima BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prima BioMed and other key companies, straight to your email. Email Address About Prima BioMedPrima BioMed (NASDAQ:IMMP), trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response. This candidate is being evaluated in multiple Phase II clinical trials across a range of solid tumors, including breast and lung cancers. Founded in 2001 and headquartered in Sydney, Australia, Prima BioMed has built its expertise in immuno-oncology over two decades of research and development. In 2018, the company rebranded as Immutep to reflect its broader strategic focus on LAG-3–based immunotherapies. Since its inception, Prima BioMed has collaborated with leading academic institutions and cancer centers worldwide to advance its clinical programs and validate the therapeutic potential of LAG-3 modulation. Prima BioMed maintains a global footprint with additional offices and research partnerships in Europe and the United States. Through collaborations with pharmaceutical partners and contract research organizations, the company aims to accelerate clinical development, streamline regulatory submissions and establish a foundation for potential commercialization. Its pipeline also includes monoclonal antibodies targeting LAG-3 and other immune checkpoints, underscoring a commitment to expanding treatment options for patients with hard-to-treat malignancies.View Prima BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI MoatMedtronic’s Stars Are Aligning for a Price RecoverySalesforce Looks Overbought, But the Rally May Be Far From OverIs Abercrombie & Fitch's Hot Streak Just Getting Started?Dutch Bros Sell-Off Creates a Growth OpportunityQualcomm’s AI Ambitions Run Into a Smartphone Reality CheckPalantir’s Sovereign AI Pitch Tests Microsoft’s Cloud-First AI Bet Upcoming Earnings Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
